180 Life Sciences 

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PALO ALTO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Treatments for early stage Dupuytren's disease: an evidence-based approach' in The Journal of Hand Surgery (European Volume) .

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren's Disease

NEW YORK--( BUSINESS WIRE )--Newman Ferrara LLP announced today that it has an ongoing investigation into actions taken by officers and directors of KBL Merger Corp. IV (“KBL”), a special purpose acquisition company (“SPAC”) in connection to its merger with 180 Life Sciences Corp. (NASDAQ:ATNF) (the “Merger”) that was completed on November 6, 2020.

Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)

Nokia

Tonix Pharmaceuticals Hld

Are you using the news to find penny stocks to buy? The post Using News to Find Penny Stocks to Buy: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Using News to Find Penny Stocks to Buy: 3 Tips

AST SpaceMobile

Cosmos Holdings

Canoo

IMARA

Marathon Digital Holdings

Redfin

Short squeeze penny stocks to watch this week. The post Penny Stocks To Buy This Week?

Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch

PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Dupuytren's disease: a localized and accessible human fibrotic disorder' in the journal Trends in Molecular Medicine .

180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren's Disease

Short Squeeze Penny Stocks To Watch At The Start Of 2023. The post Penny Stocks To Buy This Week?

Penny Stocks To Buy This Week? 4 Short Squeeze Stocks To Watch

Dermata Therapeutics

Silo Pharma Inc

Are you using these penny stocks trading strategies? The post 3 Essential Strategies for Penny Stocks Trading in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Essential Strategies for Penny Stocks Trading in 2023

PALO ALTO, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Dear Fellow Shareholder,

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

Baudax Bio

Carvana

Digital Brands Group Inc

Embark Technology

Arcimoto

Missfresh Ltd

With a contentious time in 2022 coming to a close, it may be helpful to look back and consider the most sold-off stocks last year. Similar to learning from prior mistakes, investors may be able to garner lessons from the worst-hit market ideas.

The 7 Most Sold-Off Stocks of 2022

PALO ALTO, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules with a single healthcare-focused U.S. institutional investor of 1,714,286 shares of the Company's common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,571,429 shares of common stock at a purchase price per share (and accompanying warrant) of $3.50. The warrants have an exercise price of $3.50 per share, are initially exercisable beginning six months following the date of issuance and expire five years from the initial exercise date.

180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

PALO ALTO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) --  180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor, for the purchase and sale of 1,714,286 shares of the Company's common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,571,429 shares of common stock at a purchase price per share (and accompanying warrant) of $3.50 in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.50 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years from the initial exercise date.

180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

A 1-for-20 reverse split of 180 Life Sciences (ATNF) stock has gone into effect. These are the details.

180 Life Sciences (ATNF) Stock: 1-For-20 Reverse Split Goes Into Effect

PALO ALTO, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will effect a one-for-20 reverse stock split (“reverse split”) of its common stock, $0.0001 par value per share (“Common Stock”), that will become effective on December 19, 2022 at 12:01 a.m. EST. The shares of the Company's common stock are expected to begin trading on the NASDAQ Capital Market (“NASDAQ”) on a post-split basis on December 19, 2022. No change was made to the trading symbol for the Company's shares of common stock or public warrants, “ATNF” and “ATNFW”, respectively, in connection with the reverse split.

180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan

PALO ALTO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company and its regulatory consultants from the US and the UK, met with the UK Medicines and Healthcare products Regulatory Agency (MHRA) scientific advice committee for the second time on October 31, 2022. The Company provided additional data to MHRA concerning the use of nodule size and hardness as surrogate markers relating to eventual finger contraction in Dupuytren's disease, and raised a series of questions to MHRA. On November 23, 2022, the Company received formal written scientific advice regarding such matters.

180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren's Contracture

PALO ALTO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will participate in A.G.P.'s Virtual Biotech Conference to be held November 30 – December 1, 2022.

180 Life Sciences to Participate in A.G.P.'s Virtual Biotech Conference to be Held November 30 – December 1, 2022

PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated under the same headline on Thursday, November 15th by 180 Life Sciences Corp. An embedded link has been added to the 5th paragraph. The complete and corrected release follows.

CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren's Disease

PALO ALTO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody.

180 Life Sciences Issues Letter to Stockholders

PALO ALTO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company announced that the first patient has been randomized in the clinical trial to evaluate anti-tumor necrosis factor (TNF) for patients with early-stage, pain predominant frozen shoulder.

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

PALO ALTO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that a team led by researchers at University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) in the U.K. to conduct a feasibility trial to investigate whether anti-tumor necrosis factor (TNF) therapy, administered at the time of surgery, can reduce or prevent post operative delirium/cognitive deficit (“post-operative delirium”).

180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program Wi

PALO ALTO, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor, for the purchase and sale of 6,132,076 shares of the Company's common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 6,132,076 shares of common stock at a purchase price per share (and accompanying warrant) of $1.06 in a registered direct offering. The warrants will have an exercise price of $1.06 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years from the initial exercise date.

180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering

PALO ALTO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the "Company"), a clinical-stage biotechnology company today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody.

180 Life Sciences Corp. Issues Letter to Stockholders

180 Life Sciences Corp (NASDAQ: ATNF) received a written response from the U.K.'s regulatory agency and U.S. FDA related to questions submitted in a Type C meeting request for anti-TNF treatment, adalimumab, to treat early-stage Dupuytren's disease. Dupuytren's disease.

Why 180 Life Sciences Shares Are Plunging Today

PALO ALTO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced receipt of a written response from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and from the U.S. Food and Drug Administration (FDA) related to questions submitted in a Type C meeting request on the Company's planned use of anti-TNF treatment, adalimumab, to treat early-stage Dupuytren's disease

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren's Disease

PALO ALTO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced, following publication of promising data from a Phase 2b Dupuytren's trial in the June 2022 issues of The Lancet Rheumatology, that 180 Life Sciences has initiated preliminary consultations with regulatory agencies in both the UK and USA, with the assistance of Kinexum, the Company's regulatory advisor.

180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren's Disease

PALO ALTO, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, in collaboration with the University of Oxford, today announced final results from its Phase 2b study in patients with Dupuytren's disease. The positive data results were published today in The Lancet Rheumatology.

News for 180 Life Sciences Stock (ATNF)